Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 3 Recurrence 1 Rectal Neoplasms 1 Neuroendocrine Tumors 1 Melanoma 1 Lymphoma, T-Cell, Peripheral 1 Leukemia, Myeloid, Acute 1 Leukemia, Erythroblastic, Acute 1 Hodgkin Disease 1 Breast Neoplasms 1 Brain Neoplasms 1

Interventions

Cyclophosphamide 45 Prednisone 31 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 29 Vincristine 28 Doxorubicin 27 Etoposide 22 romidepsin 20 Gemcitabine 18 Lenalidomide 16 10-propargyl-10-deazaaminopterin 16 fludarabine phosphate 15 Whole-Body Irradiation 15 Peripheral Blood Stem Cell Transplantation 14 Brentuximab Vedotin 14 Azacitidine 13 Mycophenolic Acid 12 Dexamethasone 10 Cyclosporine 10 Bortezomib 10 Alemtuzumab 10 Rituximab 8 fludarabine 7 belinostat 7 Methotrexate 6 Cytarabine 6 Busulfan 6 Bendamustine Hydrochloride 6 pembrolizumab 5 denileukin diftitox 5 Nivolumab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, T-Cell, Peripheral × Salvage Therapy × Clear all

NCT07470996 2026-03-13

T-START-NR

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon ⚡